查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
質子泵抑制劑的全球市場——2022-2029
市場調查報告書
商品編碼
1146404

質子泵抑制劑的全球市場——2022-2029

Global Proton Pump Inhibitors Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

質子泵抑制劑的市場規模預計到 2021 年將達到 30 億美元，到 2029 年將達到 40 億美元，在預測期內（2022-2029 年）以 4.9% 的複合年增長率增長。 .

質子泵抑制劑 (PPI) 是主要用於顯著和持續降低胃酸過多、胃食管反流病和潰瘍患者胃酸水平的藥物。

市場動態

市場的增長在很大程度上是由消化性潰瘍和其他胃腸道疾病的增加推動的，這是推動創新藥物輸送系統被接受的主要因素之一。此外，新產品的推出和消費者對新給藥技術接受度的提高為市場參與者提供了巨大的發展潛力。

GERD 患病率上升和新的給藥系統有望推動市場增長

推動市場增長的兩個因素是胃食管反流病 (GERD) 患病率的上升和對創新藥物輸送技術的日益接受。質子泵抑製劑是 GERD 的標準治療方法。

此外，諸如年齡、肥胖、胃排空延遲、與吸煙相關的習慣改變以及使用酒精、咖啡、高脂肪和油炸食品等風險因素是引起 GERD 的主要原因。根據聯合國《世界人口老齡化報告》，2020年65歲及以上人口有7.27億，預計到2050年將增至15億。

此外，進入市場的主要公司正在開發新產品並推出新產品，以預測市場的未來潛力。例如，新澤西州 Insood Pharmaceuticals 的仿製藥子公司 Xiromed LLC 於 2021 年 3 月推出了奧美拉唑緩釋膠囊 20mg，這是 Prirose 的仿製藥。這些藥物的上市正在加速市場的擴張。

與質子泵抑制劑相關的副作用是市場增長的主要障礙

質子泵抑制劑存在結腸艱難梭菌感染的風險。長期使用 PPI 還可能增加與骨質疏鬆相關的髖部、腕部和脊柱骨折的風險。

COVID-19 影響分析

多項研究表明，服用質子泵抑制劑的人感染 COVID-19 的風險增加。該研究在 2020 年 8 月的一篇題為“質子泵抑制劑使用者增加感染 COVID-19 的風險”的文章中有所描述，涉及超過 53,000 名質子泵抑製劑使用者，其中 3,386 人患有 COVID-19。已報告 19 例陽性反應。建議接受質子泵抑制劑治療的患者減少藥物攝入量，除非在緊急情況下避免使用這些藥物。預計這將影響市場增長。因此，COVID-19將對增加截肢的調查市場的擴大產生相當大的影響。

行業分析

全球質子泵抑製劑市場根據波特五力分析、監管分析、報銷分析、供應鏈分析、定價分析和管道分析等各種行業因素對市場進行了深入分析。

細分分析

埃索美拉唑細分市場有望在全球質子泵抑製劑市場佔據最大市場份額

埃索美拉唑預計將佔大部分收入，因為它主要用於治療 GERD、胃灼熱和其他胃酸過多的症狀和問題。此外，即將到來的從非處方藥到處方藥的轉變可能會對銷售產生重大影響。

此外，市場上的主要競爭對手正專注於研發和市場拓展工作，以向市場推出新的可靠配方。例如，2020 年 7 月，Cadila Pharmaceuticals 在印度推出了商品名為 Esiloc 的埃索美拉唑片，用於治療胃酸過多和藥物性胃炎。

市場進入者的戰略行動也在加速這一細分市場的擴張。例如，2021年3月，第一三共株式會社從日本阿斯利康手中收購了質子泵抑製劑耐信10mg和20mg膠囊以及耐信10mg和20mg懸浮顆粒（埃索美拉唑鎂）的銷售和分銷權。

區域分析

北美在質子泵抑制劑的全球市場中佔有最大的市場份額

北美目前在質子泵抑制劑市場佔據主導地位，預計在預測期內將繼續佔據主導地位，且不會出現明顯變化。然而，由於不健康生活方式的增加，GERD 在美國、加拿大和墨西哥變得越來越普遍。根據美國國家糖尿病、消化和腎臟疾病研究所 2020 年的統計數據，大約 20% 的美國人患有 GERD。

質子泵抑製劑是美國最常用的處方藥之一，在過去幾年中，美國門診 PPI 的使用量激增。許多公司還在品牌推廣方面進行了大量投資。美國醫師學會注意到 PPI 的使用越來越多，並發起了一項鼓勵正確使用 PPI 的運動。

此外，仿製藥的上市有望對市場產生影響。例如，雷迪博士實驗室有限公司於 2021 年 2 月推出了口腔崩解片蘭索拉唑 DR。本品為 Prevacidsolutab 緩釋口腔崩解片 15mg、30mg 的治療等效仿製藥，已獲得美國食品和藥物管理局 (USFDA) 批准。此類仿製藥的推出正在加速市場的擴張。

內容

第 1 章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

  • 按藥物類型劃分的市場細分
  • DataM CLO 場景

第 4 章市場動態

  • 市場影響因素
    • 促進因素
      • 胃食管反流病 (GERD) 患病率增加
      • 新藥物輸送系統的採用範圍擴大
  • 抑制因素
    • 增加仿製藥的使用
  • 影響分析

第 5 章行業分析

  • 波特五力分析
  • 監管分析
  • 供應鏈分析
  • 流行病學分析
  • 管道分析
  • 保險報銷分析
  • 未滿足的需求

第 6 章按藥物類型分類

  • 非處方藥
    • Omeprazole
    • Lansoprazole
    • Esomeprazole
    • 其他非處方藥
  • 處方藥
    • Rabeprazole
    • Dexlansoprazole
    • Pantoprazole
    • 其他藥物

第 7 章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 8 章競爭格局

  • 競爭場景
  • 競爭性質子泵抑製劑策略分析
  • 比較產品組合分析
  • 市場情況/份額分析
  • 併購分析

第 9 章公司簡介

  • Bayer AG
    • 公司簡介
    • 產品組合和說明
    • 主要亮點
    • 財務摘要
  • AstraZeneca
  • Pfizer, Inc
  • Eli-Lilly
  • Teva Pharmaceuticals
  • Cadila pharmaceuticals
  • Janssen Global Services
  • Takeda Pharmaceuticals
  • Eisai Pharmaceuticals

第 10 章質子泵抑制劑的全球市場-DataM

簡介目錄
Product Code: DMPH1407

Market Overview

Proton Pump Inhibitors Market size was valued US$ 3.0 billion in 2021 and is estimated to reach US$ 4.0 billion by 2029, growing at a CAGR of 4.9% during the forecast period (2022-2029).

Proton pump initiators (PPIs) are medications that are primarily used to significantly and persistently reduce the levels of stomach acid in people with hyperacidity, gastroesophageal reflux disease, and ulcers.

Market Dynamics

The growth of the market is majorly driven by increasing number of peptic ulcers and other gastrointestinal problems, one of the primary factors driving the acceptance of innovative drug delivery systems. In addition, new product introductions and rising consumer acceptance of novel medicine delivery technologies present market players with enormous development potential.

Increasing prevalence of GERD coupled with novel drug delivery systems are expected to drive market growth

The two main drivers driving the growth of the market are the rising prevalence of gastroesophageal reflux disease (GERD) and the expanding acceptability of innovative medication delivery technologies. Proton pump inhibitors are the gold standard treatments for GERD.

Additionally, the main causes of GERD include risk factors like age, obesity, delayed stomach emptying, changing smoking-related habits, and use of alcohol, coffee, fatty, and fried meals. Furthermore, according to a report by the United Nations titled "World Population Ageing Report, 2020," there were 727 million individuals in the world who were 65 or older as of 2020, and that figure is expected to increase to 1.5 billion by 2050.

Additionally, major industry participants are developing novel products and launching new products to take advantage of market prospects. For instance, the generic version of Prilose, Omeprazole Delayed-Release Capsules, 20mg, was introduced in March 2021 by Xiromed LLC, the generic subsidiary of Insud Pharmaceuticals in New Jersey. Such medicine launches are accelerating the market's expansion.

The side effects associated with the proton pump inhibitors are the major factors hindering the growth of the market

Proton pump inhibitors lead to a risk of Clostridium difficile infection of the colon. Also, the long-term usage of PPI may increase risk of osteoporosis-related fractures of the hip, wrist, or spine.

COVID-19 Impact Analysis

Numerous studies have shown that people taking proton pump inhibitors have a higher risk of COVID-19. More than 53,000 users of proton pump inhibitors took part in the study described in the August 2020 article titled "Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors," 3,386 of whom reported having tested positive for COVID-19. Patients undergoing proton-pump inhibitor therapy are encouraged to consume fewer drugs and avoid these medications unless there is an emergency. This factor is expected to impact market growth. Therefore, COVID-19 considerably affects the expansion of the market under investigation.an increase in amputations.

Industry Analysis

The global proton pump inhibitors market provides in-depth analysis of the market based on various industry factors such as porter's five forces, regulatory analysis, reimbursement analysis, supply chain analysis, pricing analysis, pipeline analysis etc.

Segment Analysis

Esomeprazole segment is expected to hold the largest market share in global proton pump inhibitors market

Since it is mainly used to treat the signs and symptoms of GERD, heartburn, and other problems involving excessive stomach acids, esomeprazole is anticipated to account for a sizeable portion of the income. Additionally, the drug's imminent transition from an over-the-counter (OTC) drug to a prescription-only medication will likely impact sales considerably.

Major market competitors are also concentrating on R&D and market expansion initiatives to introduce new and dependable formulations to the market. For instance, in July 2020, Cadila Pharmaceuticals introduced esomeprazole tablets under the trade name Esiloc in India to treat hyperacidity and medication-induced gastritis.

The market participants' strategic actions are also accelerating the segment's expansion. For example, in March 2021 Daiichi Sankyo Co., Ltd. gave AstraZeneca in Japan the marketing and distribution rights for the proton pump inhibitor Nexium 10 mg and 20 mg capsules and Nexium 10 mg and 20 mg granules for suspension (esomeprazole magnesium).

Geographical Analysis

North America region holds the largest market share in the global proton pump inhibitors market

North America presently dominates the proton pump inhibitors market, and it is predicted that it will continue to do so during the forecast period without experiencing any notable changes. However, due to a rise in unhealthy lifestyles, GERD is becoming more prevalent in the United States, Canada, and Mexico. About 20% of Americans, according to the National Institute of Diabetes and Digestive and Kidney Diseases Statistics of 2020, have GERD.

Proton pump inhibitors are one of the most commonly prescribed medications in the US, and during the past few years, ambulatory settings throughout the country have seen an upsurge in PPI use. Additionally, many companies are investing extensively in brand promotion. The American Board of Internal Medicine took notice of the growing usage of PPIs and launched a campaign to encourage their proper use.

Additionally, it is anticipated that generic product launches will affect the market. As an illustration, Dr Reddy's Laboratories Ltd. introduced lansoprazole DR, orally disintegrating tablets, in February 2021. This product is a therapeutically equivalent generic version of Prevacid soluTab delayed-release orally disintegrating tablets, 15 mg and 30 mg, and it has received approval from the US Food and Drug Administration (USFDA). Such generic medicine introductions are accelerating the market's expansion.

Competitive Landscape

The proton pump inhibitors market is highly competitive, owing to the presence of big brands. Also, the market is highly fragmented due to the presence of several large and regional players. The key players which are contributing to the growth of the global market include Bayer, AstraZeneca, Pfizer, Inc, Eli-Lilly, Teva Pharmaceuticals, Cadila pharmaceuticals, Janssen Global Services, Takeda Pharmaceuticals and Eisai Pharmaceuticals.

Key Companies to Watch

Pfizer Inc:

Overview: Pfizer Inc. is an American multinational pharmaceutical company that offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer Limited has a portfolio of over 150 products across 15 therapeutic areas. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology. The company also offers orthodontic solutions, Proton Pump Inhibitors solutions, surgical devices, consumer health, micro fluidics, medical grade tapes and adhesive technologies to medical device manufacturers.

Product Portfolio: PROTONIX- PROTONIX is a proton pump inhibitor indicated for short-Term treatment of erosive esophagitis associated with gastroesophageal reflux disease (GERD).

The global proton pump inhibitors market report would provide an access to an approx. 45+ market data table, 40+ figures and 180 pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Drug types
  • 3.2. DataM CLO Scenario

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing prevalence of gastroesophageal reflux disease (GERD)
      • 4.1.1.2. Increasing acceptance of novel drug delivery systems
  • 4.2. Restraints
    • 4.2.1. Increasing use of generic drugs
  • 4.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porters Five Forces Analysis
  • 5.2. Regulatory Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Epidemiology Analysis
  • 5.5. Pipeline Analysis
  • 5.6. Reimbursement Analysis
  • 5.7. Unmet Needs

6. By Drug Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug type
    • 6.1.2. Market Attractiveness Index, By Drug Type
  • 6.2. Over the Counter Drugs
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 6.2.3. Omeprazole
    • 6.2.4. Lansoprazole
    • 6.2.5. Esomeprazole
    • 6.2.6. Other OTC Drugs
  • 6.3. Prescription Drugs
    • 6.3.1. Rabeprazole
    • 6.3.2. Dexlansoprazole
    • 6.3.3. Pantoprazole
    • 6.3.4. Other Prescription Drugs

7. By Region

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 7.3. Market Attractiveness Index, By Region
  • 7.4. North America
    • 7.4.1. Introduction
    • 7.4.2. Key Region-Specific Dynamics
    • 7.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug type
    • 7.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 7.4.4.1. US
      • 7.4.4.2. Canada
      • 7.4.4.3. Mexico
  • 7.5. Europe
    • 7.5.1. Introduction
    • 7.5.2. Key Region-Specific Dynamics
    • 7.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug type
    • 7.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 7.5.4.1. Germany
      • 7.5.4.2. UK
      • 7.5.4.3. France
      • 7.5.4.4. Italy
      • 7.5.4.5. Spain
      • 7.5.4.6. Rest of Europe
  • 7.6. South America
    • 7.6.1. Introduction
    • 7.6.2. Key Region-Specific Dynamics
    • 7.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug type
    • 7.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 7.6.4.1. Brazil
      • 7.6.4.2. Argentina
      • 7.6.4.3. Rest of South America
  • 7.7. Asia Pacific
    • 7.7.1. Introduction
    • 7.7.2. Key Region-Specific Dynamics
    • 7.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug type
    • 7.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 7.7.4.1. China
      • 7.7.4.2. India
      • 7.7.4.3. Japan
      • 7.7.4.4. Australia
      • 7.7.4.5. Rest of Asia Pacific
  • 7.8. Middle East and Africa
    • 7.8.1. Introduction
    • 7.8.2. Key Region-Specific Dynamics
    • 7.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug type

8. Competitive Landscape

  • 8.1. Competitive Scenario
  • 8.2. Competitor Proton Pump Inhibitor Strategy Analysis
  • 8.3. Comparative Product Portfolio Analysis
  • 8.4. Market Positioning/Share Analysis
  • 8.5. Mergers and Acquisitions Analysis

9. Company Profiles

  • 9.1. Bayer AG
    • 9.1.1. Company Overview
    • 9.1.2. Product Portfolio and Description
    • 9.1.3. Key Highlights
    • 9.1.4. Financial Overview
  • 9.2. AstraZeneca
  • 9.3. Pfizer, Inc
  • 9.4. Eli-Lilly
  • 9.5. Teva Pharmaceuticals
  • 9.6. Cadila pharmaceuticals
  • 9.7. Janssen Global Services
  • 9.8. Takeda Pharmaceuticals
  • 9.9. Eisai Pharmaceuticals

(LIST NOT EXHAUSTIVE)

10. Global Proton Pump Inhibitors Market - DataM

  • 10.1. Appendix
  • 10.2. About Us and Services
  • 10.3. Contact Us